Background and aims: Breast cancer is the most common cancer in women and the second leading cause of cancer-related deaths in this population. Breast cancer related deaths have declined due to screening and adjuvant therapies, yet a driving clinical need exists to better understand the cause of the deadliest aspect of breast cancer, metastatic disease. Breast cancer metastasizes to several distant organs, the liver being the third most common site. To date, very few murine models of hepatic breast cancer exist.
Methods: In this study, a novel murine model of liver breast cancer using the MDA-MB-231 cell line is introduced as an experimental (preclinical) model.
Results: Histological typing revealed consistent hepatic breast cancer tumor foci. Common features of the murine model were vascular invasion, lung metastasis and peritoneal seeding.
Conclusions: The novel murine model of hepatic breast cancer established in this study provides a tool to be used to investigate mechanisms of hepatic metastasis and to test potential therapeutic interventions.
Keywords: AFP, Alpha Fetal Protein; Ad:uPA, Adenovirus Urokinase Plasminogen Activator; Breast cancer; DMEM, Dulbecco's Modified Eagle Medium; FRG™ KO, [ Fah(-/-) R ag2(-/-)Il2r g (-/-)]); GPC3, Glypican-3; HCM, Hepatocyte Culture Medium; HER2, human epidermal growth factor receptor 2; Hep Par 1, Hepatocyte Paraffin 1; IACUC, Institutional Animal Care and Use Committee; Liver metastasis; NOD, Non-obese diabetic; Preclinical model; pfu, plaque forming units.